Literature DB >> 20591831

Idiopathic inflammatory myopathies, signified by distinctive peripheral cytokines, chemokines and the TNF family members B-cell activating factor and a proliferation inducing ligand.

Peter Szodoray1, Philip Alex, Nicholas Knowlton, Michael Centola, Igor Dozmorov, Istvan Csipo, Annamaria T Nagy, Tamas Constantin, Andrea Ponyi, Britt Nakken, Katalin Danko.   

Abstract

OBJECTIVE: Serum cytokines play an important role in the pathogenesis of myositis by initiating and perpetuating various cellular and humoral autoimmune processes. The aim of the present study was to describe a broad spectrum of T- and B-cell cytokines, growth factors and chemokines in patients with idiopathic inflammatory myopathies (IIMs) and healthy individuals.
METHODS: A protein array system, denoted as multiplex cytokine assay was utilized to measure simultaneously the levels of 24 circulating cytokines, including B-cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) of patients with IIMs and healthy individuals. Additionally, correlational clustering and discriminant function analysis (DFA), two multivariate, supervised analysis methods were employed to identify a subset of biomarkers in order to describe potential functional interrelationships among these pathological cytokines.
RESULTS: Univariate analysis demonstrated that a complex set of immune and inflammatory modulating cytokines are significantly up-regulated in patients with IIMs relative to unaffected controls including IL-10, IL-13, IFN-α, epidermal growth factor (EGF), VEGF, fibroblast growth factor (FGF), CCL3 [macrophage inflammatory protein (MIP-1α)], CCL4 (MIP-1β) and CCL11 (eotaxin), whereas G-CSF was significantly reduced in IIM patients. Correlational clustering was able to discriminate between, and hence sub-classify patients with IIMs. DFA identified EGF, IFN-α, VEGF, CCL3 (MIP-1α) and IL-12p40, as analytes with the strongest discriminatory power among various myositis patients and controls.
CONCLUSIONS: Our findings suggest that these factors modulate myositis pathology and help to identify differences between subsets of the disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20591831      PMCID: PMC2936946          DOI: 10.1093/rheumatology/keq151

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  46 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  TALL-1 is a novel member of the TNF family that is down-regulated by mitogens.

Authors:  H B Shu; W H Hu; H Johnson
Journal:  J Leukoc Biol       Date:  1999-05       Impact factor: 4.962

3.  Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjögren's syndrome.

Authors:  Malin V Jonsson; Peter Szodoray; Stig Jellestad; Roland Jonsson; Kathrine Skarstein
Journal:  J Clin Immunol       Date:  2005-05       Impact factor: 8.317

4.  Cluster analysis and display of genome-wide expression patterns.

Authors:  M B Eisen; P T Spellman; P O Brown; D Botstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

Review 5.  The TNF family members BAFF and APRIL: the growing complexity.

Authors:  Fabienne Mackay; Christine Ambrose
Journal:  Cytokine Growth Factor Rev       Date:  2003 Jun-Aug       Impact factor: 7.638

6.  Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls.

Authors:  I Lundberg; J M Brengman; A G Engel
Journal:  J Neuroimmunol       Date:  1995-12       Impact factor: 3.478

7.  Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases.

Authors:  Katalin Dankó; Andrea Ponyi; Tamás Constantin; Gábor Borgulya; Gyula Szegedi
Journal:  Medicine (Baltimore)       Date:  2004-01       Impact factor: 1.889

8.  BLyS/BAFF: a potential target in the treatment of active systemic lupus erythematosus.

Authors:  Elias Toubi; Yehuda Shoenfeld
Journal:  Isr Med Assoc J       Date:  2004-02       Impact factor: 0.892

9.  BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth.

Authors:  P Schneider; F MacKay; V Steiner; K Hofmann; J L Bodmer; N Holler; C Ambrose; P Lawton; S Bixler; H Acha-Orbea; D Valmori; P Romero; C Werner-Favre; R H Zubler; J L Browning; J Tschopp
Journal:  J Exp Med       Date:  1999-06-07       Impact factor: 14.307

10.  APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth.

Authors:  M Hahne; T Kataoka; M Schröter; K Hofmann; M Irmler; J L Bodmer; P Schneider; T Bornand; N Holler; L E French; B Sordat; D Rimoldi; J Tschopp
Journal:  J Exp Med       Date:  1998-09-21       Impact factor: 14.307

View more
  27 in total

1.  Statistical insights into major human muscular diseases.

Authors:  Shakti Gupta; Sung-Min Kim; Yu Wang; Ashok Reddy Dinasarapu; Shankar Subramaniam
Journal:  Hum Mol Genet       Date:  2014-02-25       Impact factor: 6.150

2.  Novel approaches in the treatment of myositis and myopathies.

Authors:  Jemima Albayda; Lisa Christopher-Stine
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-10       Impact factor: 5.346

Review 3.  The Immune Response and the Pathogenesis of Idiopathic Inflammatory Myositis: a Critical Review.

Authors:  Angela Ceribelli; Maria De Santis; Natasa Isailovic; M Eric Gershwin; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

Review 4.  Cytokine Milieu in Undifferentiated Connective Tissue Disease: a Comprehensive Review.

Authors:  Britt Nakken; Edit Bodolay; Peter Szodoray
Journal:  Clin Rev Allergy Immunol       Date:  2015-10       Impact factor: 8.667

Review 5.  Pathogenesis of dermatomyositis: role of cytokines and interferon.

Authors:  Lily Kao; Lorinda Chung; David F Fiorentino
Journal:  Curr Rheumatol Rep       Date:  2011-06       Impact factor: 4.592

Review 6.  Causes and consequences of endoplasmic reticulum stress in rheumatic disease.

Authors:  Fatemeh Navid; Robert A Colbert
Journal:  Nat Rev Rheumatol       Date:  2016-12-01       Impact factor: 20.543

Review 7.  Pathogenesis, classification and treatment of inflammatory myopathies.

Authors:  Mei Zong; Ingrid E Lundberg
Journal:  Nat Rev Rheumatol       Date:  2011-04-05       Impact factor: 20.543

8.  Endothelial Activation Markers as Disease Activity and Damage Measures in Juvenile Dermatomyositis.

Authors:  Takayuki Kishi; Jonathan Chipman; Melvina Evereklian; Khanh Nghiem; Maryalice Stetler-Stevenson; Margaret E Rick; Michael Centola; Frederick W Miller; Lisa G Rider
Journal:  J Rheumatol       Date:  2019-08-01       Impact factor: 4.666

Review 9.  Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research.

Authors:  Lisa G Rider; Katalin Dankó; Frederick W Miller
Journal:  Curr Opin Rheumatol       Date:  2014-11       Impact factor: 5.006

Review 10.  The tumor necrosis factor superfamily of cytokines in the inflammatory myopathies: potential targets for therapy.

Authors:  Boel De Paepe; Kim K Creus; Jan L De Bleecker
Journal:  Clin Dev Immunol       Date:  2011-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.